Stern F B, Murthy L I, Beaumont J J, Schulte P A, Halperin W E
J Occup Med. 1985 Jul;27(7):495-500.
A retrospective cohort mortality study was conducted among workers employed at the last facility in the United States that manufactured beta-naphthylamine (BNA), a recognized human bladder carcinogen. This study was conducted in conjunction with a pilot project in which workers were notified of the health risks associated with exposures to carcinogenic amines. Cause-specific mortality for 1,312 male workers employed between 1940 and 1972, and followed through 1979, was compared with the mortality of the general population in the United States. Two deaths from bladder cancer were observed while 0.7 such deaths were expected. Due to the use of these potent carcinogenic amines, it had been anticipated that more bladder cancer deaths would be found in this population. The reasons for the small number of bladder cancer deaths could have been the low percentage of the work force exposed, an inadequate latency period, and/or the high survival rate for bladder cancer. In fact, a notification and medical screening project recently conducted in this same population found an additional 11 bladder cancer cases. This suggests that mortality may not always be an adequate indicator of disease risk.
在美国最后一家生产β-萘胺(BNA,一种公认的人类膀胱致癌物)的工厂工作的工人中进行了一项回顾性队列死亡率研究。这项研究是与一个试点项目同时进行的,在该试点项目中,工人们被告知与接触致癌胺相关的健康风险。将1940年至1972年受雇并随访至1979年的1312名男性工人的特定病因死亡率与美国普通人群的死亡率进行了比较。观察到两例膀胱癌死亡,而预期为0.7例。由于使用了这些强效致癌胺,预计在该人群中会发现更多的膀胱癌死亡病例。膀胱癌死亡人数较少的原因可能是接触劳动力的比例较低、潜伏期不足和/或膀胱癌的高生存率。事实上,最近在同一人群中开展的一项通知和医学筛查项目又发现了11例膀胱癌病例。这表明死亡率可能并不总是疾病风险的充分指标。